Details of the Drug

General Information of Drug (ID: DM1874J)

Drug Name
TRC105
Indication
Disease Entry ICD 11 Status REF
Angiosarcoma 2B56 Phase 3 [1]
Hemangiosarcoma 2B56.1 Phase 3 [2]
Fallopian tube cancer 2C74 Phase 2 [3]
Gestational trophoblastic neoplasia 2F33-2F76 Phase 2 [2]
Hepatocellular carcinoma 2C12.02 Phase 2 [2]
Macular degeneration 9B78.3 Phase 2 [3]
Ovarian cancer 2C73 Phase 2 [3]
Peritoneal cancer 2C51.Z Phase 2 [3]
Recurrent glioblastoma 2A00.00 Phase 2 [4]
Renal cell carcinoma 2C90 Phase 2 [2]
Soft tissue sarcoma 2B57 Phase 2 [5]
Breast cancer 2C60-2C65 Phase 1 [2]
Lung cancer 2C25.0 Phase 1 [2]
⏷ Show the Full List of Indication(s)
Drug Type
Monoclonal antibody
Cross-matching ID
TTD ID
D00YQI
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Endoglin CD105 (ENG) TTB30LE EGLN_HUMAN Modulator [6]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 ClinicalTrials.gov (NCT02979899) Trial of TRC105 and Pazopanib Versus Pazopanib Alone in Patients With Advanced Angiosarcoma (TAPPAS). U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 ClinicalTrials.gov (NCT01727089) Bevacizumab With or Without TRC105 in Treating Patients With Metastatic Kidney Cancer. U.S. National Institutes of Health.
4 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
6 An open-label phase Ib dose-escalation study of TRC105 (anti-endoglin antibody) with bevacizumab in patients with advanced cancer. Clin Cancer Res. 2014 Dec 1;20(23):5918-26.